Therma Bright Secures an Initial Limited Exclusive U.S. Marketing and Distribution Contract for Its Consumer Products with Global Wellness Products LLC
MWN-AI** Summary
Therma Bright Inc. (TSXV: THRM) has announced a significant milestone with the signing of an exclusive U.S. marketing and distribution contract with Global Wellness Products LLC, a subsidiary of Image Protect, Inc. This partnership will focus on promoting and selling Therma Bright's innovative consumer products, beginning with the InterceptCS cold sore prevention device, which is the first clinically proven product designed to prevent cold sores.
Rob Fia, CEO of Therma Bright, expressed enthusiasm about this collaboration, highlighting the potential for Global Wellness to expand their product offerings, which may include additional devices like the Benepod pain therapy device and TherOZap insect bite therapy device. This strategic alliance comes after Therma Bright’s successful marketing efforts for their Venowave product in 2024, establishing a foundation for further growth in the consumer health market.
The cold sore treatment market presents a lucrative opportunity, estimated at USD 1.02 billion in 2024 and projected to reach USD 1.57 billion by 2031. Frank Casella, CEO of Global Wellness Products, emphasized the competitive advantage of the InterceptCS device in a market primarily driven by traditional ointments and creams.
The InterceptCS device features an ergonomic design and is equipped with a disposable treatment activator, allowing it to effectively prevent cold sore occurrences. Therma Bright Inc. continues to innovate in the diagnostic and medical device sectors, and their collaboration with Global Wellness Products positions them to capture a larger share of the health and wellness industry.
As the partnership aims to enhance direct-to-consumer marketing through national e-commerce sales, investors and stakeholders are likely to monitor the implementation and success of this initiative closely.
MWN-AI** Analysis
Therma Bright Inc. (TSXV: THRM) has made a significant strategic move by securing an exclusive marketing and distribution contract in the U.S. with Global Wellness Products LLC, a subsidiary of Image Protect, Inc. This collaboration marks a pivotal expansion for Therma, particularly with the launch of its InterceptCS cold sore prevention device. Given the projected growth of the global cold sore treatment market from USD $1.02 billion in 2024 to USD $1.57 billion by 2031, this partnership positions Therma Bright to capitalize on this lucrative segment.
Investors should remain optimistic about Therma’s future prospects. The exclusive distribution rights established with Global Wellness Products allow for targeted e-commerce integration, enhancing direct-to-consumer marketing – a growing trend that empowers brands to build robust relationships with their customers. This approach not only broadens the product's visibility but also leverages online sales channels that are increasingly critical in the wellness industry.
Moreover, Therma is planning to introduce additional products like the Benepod and TherOZap devices through this partnership, suggesting a comprehensive strategy to expand its product suite and capture more market share. The company’s existing efforts to promote the Venowave device, already bolstered by the receipt of permanent HCPCS codes, further demonstrate a commitment to growth in the medical device sector.
However, potential investors should be wary of the inherent risks highlighted in Therma’s forward-looking statements. The company's future performance could significantly depend on the successful marketing of its new devices and the overall market dynamics.
In conclusion, Therma Bright's partnership with Global Wellness Products positions the company favorably to tap into growing markets. Maintaining a watchful eye on product rollouts and sales performance will be crucial for gauging investment prospects moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
National Distributor to Sell Cold Sore Prevention Device Through National Ecommerce Sales Through Direct to Consumer Marketing Efforts
Toronto, Ontario--(Newsfile Corp. - March 13, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that the Company has secured an exclusive U.S. contract for its consumer product devices with national marketing and distribution partner Global Wellness Products LLC, a subsidiary of Image Protect, Inc. — a United States Corporation publicly traded under the symbol (OTC Pink: IMTL).
"We're pleased to team up with Global Wellness Products for the sale and delivery of our cutting-edge consumer products, with the first focus being our InterceptCS cold sore prevention device," shared Rob Fia, CEO of Therma Bright. "Initially, Global Wellness will focus on the cold sore prevention solution, and then roll-in our other products - Benepod hot-and-cold pain therapy device and TherOZap insect bite therapy device. In 2024, we spent a great deal of our sales and marketing efforts promoting and distributing our Venowave following receipt of the permanent HCPCS codes. Now we're increasing our efforts towards some of our other consumer products."
"We see great opportunity within the retail marketplace to introduce Therma Bright's consumer products, including the InterceptCS ™ cold sore prevention device," expressed Frank Casella, CEO of Global Wellness Products LLC. "This proven medical device addresses the growing global cold sore treatment market*, which in 2024 was estimated at USD$1.02 Billion and is expected to grow to USD$1.57 billion over the next 7 years. The InterceptCS device fits nicely into this marketplace, which is mainly driven by ointments and creams."
* Source: Per Coherent Research - the global cold sore treatment market was estimated at USD$1.02 Billion in 2024, and is expected to reach USD$1.57 billion by 2031.
About InterceptCS ™ Cold Sore Prevention Device
The InterceptCS™ Cold Sore Prevention System Is the First Product Clinically Proven and Approved For the Prevention Of Cold Sores. This Cold Sore Prevention System is comprised of an ergonomically designed hand-held unit and a disposable treatment activator, the activator is good for preventing one cold sore occurrence.
About Global Wellness Products
Global Wellness Products is the new division of Image Protect, Inc, and was created to be a premier leader in the health and wellness products space. With over 50 years of combined experience in the direct response consumer products sector, the principals and staff at Global Wellness Products are ready to make massive inroads into the multi-billion-dollar health and wellness industry. Learn more at: https://www.globalwellnessproducts.com/
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244375
FAQ**
How does Therma Bright Inc. THRM:CC plan to distinguish the InterceptCS cold sore prevention device in a market primarily dominated by ointments and creams, and what specific marketing strategies will Global Wellness Products employ to enhance its visibility?
Considering the projected growth of the cold sore treatment market to USD$1.57 billion by 2031, what metrics will Therma Bright Inc. THRM:CC use to evaluate the success of their partnership with Global Wellness Products in capturing market share?
What are the expected timelines for rolling out additional Therma Bright products, and how will the success of the InterceptCS device influence the launch strategy for the Benepod and TherOZap devices?
Regarding the exclusive U.S. contract with Global Wellness Products, what measures will Therma Bright Inc. THRM:CC implement to ensure compliance with regulations while marketing the InterceptCS cold sore prevention device to U.S. consumers?
**MWN-AI FAQ is based on asking OpenAI questions about Therma Bright Inc. (TSXVC: THRM:CC).
NASDAQ: THRM:CC
THRM:CC Trading
-2.78% G/L:
$0.175 Last:
379,113 Volume:
$0.175 Open:
